AnaSpec’s Post

There is a pressing need for better therapies for #ovariancancer. We are therefore delighted to receive a $2m project grant from the United States Department of Defense to support our international clinical trials program for the treatment of this insidious disease using TILT-123. Our TILT® #oncolytic #immunotherapy technology modifies the tumour microenvironment activating the immune response to enable effective #cancer treatment of solid #tumors. 🔗 Read our press release: https://lnkd.in/e2yVsJEA 🔬 Discover our pipeline: https://lnkd.in/e6bA_Q6G #BioTech #Innovation #LifeSciences #pharma #Oncology #research #clinicalresearch #womenshealth

Don’t miss today at World CB & CDx! 🚀 Patrick Eimerman, VP Business Development and Partnering, SAGA Diagnostics. Presentation: Increasing Access to ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs Thursday, Sept 5, 12:45 pm EST 🗓️ Learn more about 💡: - SAGA’s ultrasensitive, lower-cost approach to MRD detection and quantification using WGS and our proprietary dPCR platform - How Structural Variants (SVs) are the ideal pan-cancer biomarker for determining MRD status - How our increased analytical sensitivity translates to improved clinical performance #oncology #mrd #residualdisease #clinicaltrials #biomarkers #liquidbiopsy

#ESMOGynae24: After decades of limited progress, a wave of innovative antibody-drug conjugates (ADCs) is finally bringing new hope to patients with #OvarianCancer patients. These novel therapies represent a paradigm shift by using antibodies to deliver potent chemotherapy agents directly to tumour cells while sparing healthy tissues. To learn more about the antibody-drug conjugates as a new frontier for #OvarianCancer read the #ESMODailyReporter editorial by Ana Oaknin 👉https://ow.ly/Sazn50Sm8em

The rapid evolution of CAR T-cell therapies in China has escalated over the past decade from the start of the first clinical trials in 2013 to the country becoming an established host for CAR T-cell-related trials by 2017. As of Jan. 31, 2024, there were more than 300 CAR T trials registered in China, surpassing the U.S. and becoming the country with the most CAR T therapy clinical trials. A new special report by BioWorld News, entitled, “China’s CAR T market comes of Age," examines the landscape of Car T therapy development in China. Download the comprehensive three-part report authored by Tamra Sami, Ruchita V Kumar M. Pharm, Ph.D., and Sahil Arora here: https://lnkd.in/g6PMn_Za #cancer #china #pharma #biotech #CarT #clinicaltrials #oncology

Developing innovative cancer treatments requires cutting-edge tools. Learn how Genmab utilized SEND Explorer, a web-based tool for non-clinical study data analysis, to streamline data analysis and boost research efficiency. Read the full case study: https://lnkd.in/ex8tcqDd #Certara #Genmab #FutureOfPharma #PharmaceuticalInnovation #DrugDevelopment #CancerResearch #DataManagement #SENDStandards #DataDriven #Nonclinical #PharmaceuticalResearch #AntibodyDrugConjugates #ComplexToxicologyData

Curious about tetrazole’s unique properties in drug design? These fascinating scaffolds are gaining traction in FDA-approved therapies for diverse conditions, from cancer to hypertension to anti-virals. What’s next in this evolving field? Read our encyclopaedic article in EJMC (D1); Tetrazoles: A multi-potent motif in drug design. Link: https://lnkd.in/geyAv-Mm

As T cell therapies are becoming a potential cancer cure, having better strategies in place for cryopreserving leukapheresis material for T cell processing and extending stability for manufacturing is critical. Join us for this webinar and hear from experts on improving T cell products by optimizing leukopaks and drug product cryopreservation. Register today: https://okt.to/zJpgNl #celltherapymanfuacturing #CDMO #CARTcells #leukopaks #cryopreservedleukopaks #webinar

❇️ Based on the phase 3 BEACON study, the BREAKWATER trial's safety lead-in cohort demonstrated the efficacy and tolerability of #encorafenib and #cetuximab with FOLFIRI chemotherapy in BRAF V600E-mutant metastatic #colorectal cancer:

🔬 Insights from ASCO 2024! Prof Christophe Dooms from University Hospitals Leuven presents the final analysis of the DESTINY-Lung02 trial. The phase 2 study compared two dosages of trastuzumab deruxtecan in heavily pretreated HER2 mutation-positive NSCLC, showing a 50% objective response rate and a median overall survival of 19 months. Discover the implications for future treatment strategies and ongoing trials. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #LungCancer #OncologyInnovation #DESTINYLung02 #NSCLC

As T cell therapies are becoming a potential cancer cure, having better strategies in place for cryopreserving leukapheresis material for T cell processing and extending stability for manufacturing is critical. Join us for this webinar and hear from experts on improving T cell products by optimizing leukopaks and drug product cryopreservation. Register today: https://okt.to/fA91UP #celltherapymanfuacturing #CDMO #CARTcells #leukopaks #cryopreservedleukopaks #webinar